Form 4: Axsome Therapeutics CEO Herriot Tabuteau Reports Stock Option and RSU Grants

CEO of Axsome Therapeutics, Herriot Tabuteau, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Summary

• Herriot Tabuteau, CEO of Axsome Therapeutics, filed a Form 4 with the SEC on February 29, 2024.
• The filing reports the grant of employee stock options and restricted stock units (RSUs) to Tabuteau on February 27, 2024.
• Tabuteau received options to purchase 87,192 shares of Axsome Therapeutics common stock at an exercise price of $0.00.
• These options vest in equal quarterly installments over four years, becoming fully vested on February 27, 2028.
• Tabuteau also received 47,886 RSUs, each representing a contingent right to receive one share of Axsome Therapeutics common stock.
• 25% of the RSUs will vest on the one-year anniversary of the grant date, with the remaining RSUs vesting in three equal annual installments, fully vesting on February 27, 2028.
• Vested shares will be delivered upon a Change in Control, separation of service, or seven years from the grant date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry, aligning management incentives with company performance and shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded biopharmaceutical companies like Axsome Therapeutics.
• Companies such as Biogen, Amgen, and Gilead Sciences also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and terms outlined in the filing are generally consistent with industry norms for executive equity grants.

Stakeholder Impact

• The grant of stock options and RSUs can positively impact shareholders by aligning management's interests with the company's long-term success.
• Employees may view the executive compensation package as a sign of the company's commitment to its leadership.

Key Dates